SLRX — Salarius Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $1.09m
- -$3.16m
Annual cashflow statement for Salarius Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -6.94 | -7.35 | -12.8 | -31.6 | -12.5 |
| Depreciation | |||||
| Non-Cash Items | -0.56 | 0.061 | 0.514 | 11.6 | 0.655 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -4.21 | -3.04 | 2.03 | 2.37 | -0.968 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -11.6 | -10.3 | -10.2 | -17.6 | -12.8 |
| Capital Expenditures | — | -0.003 | 0 | — | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 5.61 | 0 | — | -1.5 | 0 |
| Sale of Business | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 5.61 | -0.003 | 0 | -1.5 | 0 |
| Financing Cash Flow Items | 0 | — | — | — | — |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 3.58 | 17.7 | 28.3 | 1.99 | 6.64 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -2.39 | 7.38 | 18.1 | -17.1 | -6.21 |